TIAM1 (TIAM Rac1 Associated GEF 1)

Our study suggests that by antagonizing miR-214, HNF1A-AS1 activates the SEMA4D/PLEXIN-B1/TIAM/RAC pathway, facilitating EOC growth and potentially promoting M2 macrophage polarization in the tumor microenvironment. HNF1A-AS1 represents a compelling therapeutic target for treating EOC.

These findings underscore the pivotal contribution of Tiam1 upregulation to lung cancer development. Given the pivotal role of β-catenin in oncogenesis, we conclude that ABHD11-AS1-mediated sponging of miR-182-5p leads to Tiam1 upregulation and β-catenin pathway activation, thereby promoting Cr(VI)-induced pulmonary carcinogenesis.

This study identified ALOX15B, TIAM1, and TMC6 as potential risk genes and JUN, PAPSS2, and RAP1GAP as protective genes in THCA. These genes may serve as promising biomarkers and therapeutic targets for THCA, offering novel insights into precision oncology.

The translational relevance of these findings is underscored by the growth inhibition observed in patient-derived BPH organoids treated with NSC23766. In conclusion, our findings identify TIAM1 as a key driver of prostatic branching and growth, and suggest that targeting TIAM1-RAC1 signaling could be a promising therapeutic strategy for BPH.

In chemotherapy-treated patients, myCAFs were positioned at the tumor boundary, potentially acting as a barrier to tumor invasion. This study provides novel insights into CAF-related TME subtypes, offering a foundation for future therapeutic strategies targeting CAFs in PDAC.

This study identifies GPX3 and JUN as critical tumor suppressor genes in TC, with their function closely linked to T regulatory cells and follicular helper T cells. The overexpression of GPX3 and JUN demonstrates significant tumor-suppressive activity, highlighting their potential as effective therapeutic targets in combating TC.

Overall, this research contributes to a deeper understanding of the health risks associated with PFOA exposure and highlights the importance of continued monitoring and regulation of environmental pollutants to safeguard public health.

High expression of Tiam1 in pancreatic cancer promotes pancreatic cancer progression and may be a potential biomarker and therapeutic target for poor prognosis.

Lastly, we address potential future directions for research into the role of GEFs as CRC biomarkers and therapeutic targets. In this regard, leveraging the noncanonical actions of GEFs appears to provide a relatively unexplored opportunity requiring further investigation.

The overexpression of circTIAM1 is associated with the malignant progression of PTC. A high level of circTIAM1 promotes the malignancy of PTC cells via the miR-338-3p/LASP1 axis.

Cell-migration, apoptotic assay and western-blot in breast-cancer cells were performed with FGDWS and in combination with Doxorubicin (Dox)...The tumor size was reduced by the treatment of FGDWS and more reduced in combinatorial effect. The combinatorial effect of FGDWS-Dox may enhance the treatment efficacy without side-effects.